PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 15239025-1 2004 AIMS: To confirm whether a prostacyclin (prostaglandin I (2)) affects the increased TNF-alpha concentration in sera of diabetic patients, we measured serum TNF-alpha concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Prostaglandins I 41-56 tumor necrosis factor Homo sapiens 84-93 15380820-5 2004 COX-2 was responsible for the production of PGE(2) and PGI(2) in PDGF-stimulated LI90 cells. Prostaglandins I 55-59 prostaglandin-endoperoxide synthase 2 Homo sapiens 0-5 15362725-12 2004 The ratio of serum PGI to PGII level (PG I/II ratio) also correlated well with the plasma level of total ghrelin (p<0.05. r=0.31) and active ghrelin (p<0.05, r=0.27). Prostaglandins I 38-42 biglycan Homo sapiens 19-22 15362725-12 2004 The ratio of serum PGI to PGII level (PG I/II ratio) also correlated well with the plasma level of total ghrelin (p<0.05. r=0.31) and active ghrelin (p<0.05, r=0.27). Prostaglandins I 38-42 progastricsin Homo sapiens 26-30 15279598-2 2004 This mini-review focuses on the molecular mechanism of the isomerization of the prostaglandin H(2) to PGI(2)and TXA(2) by their synthases in the endoplasmic reticulum (ER) membrane coordinated with cyclooxygenase-1 or -2. Prostaglandins I 102-105 prostaglandin-endoperoxide synthase 1 Homo sapiens 198-220 15533902-1 2004 BACKGROUND: Cyclooxygenase enzymes (COX-1, COX-2, and COX-3) convert arachidonic acid to prostaglandins, prostacyclins, thromboxanes, and other hydroxy fatty acids. Prostaglandins I 105-118 mitochondrially encoded cytochrome c oxidase I Homo sapiens 36-41 15533902-1 2004 BACKGROUND: Cyclooxygenase enzymes (COX-1, COX-2, and COX-3) convert arachidonic acid to prostaglandins, prostacyclins, thromboxanes, and other hydroxy fatty acids. Prostaglandins I 105-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 15533902-1 2004 BACKGROUND: Cyclooxygenase enzymes (COX-1, COX-2, and COX-3) convert arachidonic acid to prostaglandins, prostacyclins, thromboxanes, and other hydroxy fatty acids. Prostaglandins I 105-118 mitochondrially encoded cytochrome c oxidase III Homo sapiens 54-59 15239025-5 2004 The augmented TNF-alpha concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I (2)) analogue for 5 weeks without any changes of blood glucose levels. Prostaglandins I 204-219 tumor necrosis factor Homo sapiens 14-23 14732215-9 2004 CONCLUSION: PGIS gene transfer accelerated re-endothelialization, and attenuated neointimal formation after stent implantation in atheromatous rabbit arteries, at least in part, via increased production of VEGF protein. Prostaglandins I 12-16 vascular endothelial growth factor A Oryctolagus cuniculus 206-210 15179620-4 2004 The proangiogenic effects of COX-2 are mediated primarily by three products of arachidonic metabolism: thromboxane A(2) (TXA(2)), prostaglandin E(2) (PGE(2)), and prostaglandin I(2) (PGI(2)). Prostaglandins I 163-178 prostaglandin-endoperoxide synthase 2 Homo sapiens 29-34 15179620-4 2004 The proangiogenic effects of COX-2 are mediated primarily by three products of arachidonic metabolism: thromboxane A(2) (TXA(2)), prostaglandin E(2) (PGE(2)), and prostaglandin I(2) (PGI(2)). Prostaglandins I 183-186 prostaglandin-endoperoxide synthase 2 Homo sapiens 29-34 14702352-12 2004 Finally, exogenous PGE(2) and PGI(2) were able to stimulate Ang2 under normoxic conditions. Prostaglandins I 30-33 angiopoietin 2 Homo sapiens 60-64 14965323-8 2004 Gastrointestinal toxicity has been attributed to the blockade of the COX-1 mediated generation of the cytoprotective prostanoids, such as PGE(2) and PGI(2). Prostaglandins I 149-152 mitochondrially encoded cytochrome c oxidase I Homo sapiens 69-74 15115769-1 2004 Prostacyclin synthase (PGIS), which catalyzes the conversion of prostaglandin (PG) H(2) to prostacyclin (PGI(2)), is a member of the cytochrome P-450 (P450) superfamily, CYP8A1. Prostaglandins I 23-26 prostaglandin I2 synthase Homo sapiens 0-21 15115769-1 2004 Prostacyclin synthase (PGIS), which catalyzes the conversion of prostaglandin (PG) H(2) to prostacyclin (PGI(2)), is a member of the cytochrome P-450 (P450) superfamily, CYP8A1. Prostaglandins I 23-26 prostaglandin I2 synthase Homo sapiens 170-176 12538086-1 2003 PGE(2) and PGI(2) reduce extracellular matrix deposition and their production is altered after ACE inhibitor (ACEi) treatment. Prostaglandins I 11-14 angiotensin I converting enzyme Homo sapiens 95-98 12770937-3 2003 In this study, we sought to determine whether phospholipase C (PLC) and D (PLD) activation also contributes, besides cPLA(2), to the lymphocyte-induced PGI(2) synthesis in HUVEC, and to delineate further the potential mechanisms of cPLA(2) activation triggered by the interaction of HUVEC with lymphocytes. Prostaglandins I 152-155 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 75-78 12676356-8 2003 Next, the effects of CLA incorporation into HUVECs on PGI(2) generation was determined. Prostaglandins I 54-57 selectin P ligand Homo sapiens 21-24 12623302-6 2003 Investigating the role of MAPK in the stimulation of prostacyclin induced by these three agonists, we found that both the p42/44 MAPK inhibitor PD 98059 (50 microM) and the p38 MAPK blocker SB 203580 (5 microM) prevented agonist-induced PGI(2) secretion without affecting COX-2 activity or synthesis. Prostaglandins I 237-240 mitogen activated protein kinase 14 Rattus norvegicus 173-176 12754089-6 2003 Similarly, substance P, ATP and ONO-54918-07, a stable prostaglandin I(2) agonist, induced nociceptive flexion response in ANF test at much lower doses than needed to induce biting-licking responses in ABL test. Prostaglandins I 55-70 tachykinin 1 Mus musculus 11-22 12511556-10 2003 The addition of PGE(2) and PGI(2) protected against TNFalpha-mediated apoptosis. Prostaglandins I 27-30 tumor necrosis factor Homo sapiens 52-60 12623129-10 2003 It is concluded, that the observed up-regulation of COX-2 with subsequent release of newly synthesized PGI(2) and the synergistic effect of iloprost and phorbolester on PGI(2) formation provide a positive feedback of prostaglandins on their own synthesizing enzyme. Prostaglandins I 103-106 prostaglandin-endoperoxide synthase 2 Homo sapiens 52-57 12538084-1 2003 Cyclooxygenase-1 is the primary isoform responsible for the production of cytoprotective prostaglandins (PGE(2) and PGI(2)) in the stomach. Prostaglandins I 116-119 prostaglandin-endoperoxide synthase 1 Homo sapiens 0-16 11301049-0 2001 Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Prostaglandins I 56-72 tumor necrosis factor Mus musculus 14-22 12379506-14 2002 Increased local vascular HGF production by a PGI(2) analogue may prevent endothelial injury, potentially resulting in the improvement of endothelial dysfunction. Prostaglandins I 45-48 hepatocyte growth factor Rattus norvegicus 25-28 12160947-6 2002 The beneficial actions of COX-2 appear to be mediated by the synthesis of PGE(2) and/or PGI(2). Prostaglandins I 88-91 prostaglandin-endoperoxide synthase 2 Homo sapiens 26-31 11509629-1 2001 The two cyclooxygenase (COX) isoforms, COX-1 and COX-2, both metabolize arachidonic acid to PGH(2), the common substrate for thromboxane A(2) (TXA(2)), prostacyclin (PGI(2)), and PGE(2) synthesis. Prostaglandins I 166-169 mitochondrially encoded cytochrome c oxidase I Homo sapiens 39-44 11509629-1 2001 The two cyclooxygenase (COX) isoforms, COX-1 and COX-2, both metabolize arachidonic acid to PGH(2), the common substrate for thromboxane A(2) (TXA(2)), prostacyclin (PGI(2)), and PGE(2) synthesis. Prostaglandins I 166-169 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-54 11509629-5 2001 By contrast, COX-2 up-regulation was associated with large increases in the synthesis of PGI(2) and PGE(2) (54- and 84-fold increases, respectively). Prostaglandins I 89-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11509629-6 2001 Addition of the selective COX-2 inhibitor, NS-398, almost completely abolished PGI(2) and PGE(2) synthesis, but had little effect on TXA(2) synthesis. Prostaglandins I 79-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 11509629-10 2001 The apparent PGI(2) and PGE(2) linkage with COX-2 activity may be explained by a temporal increase in total COX activity, together with selective up-regulation of PGI synthase and PGE synthase, and different kinetic characteristics of the terminal synthases. Prostaglandins I 13-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 11509803-9 2001 PGE(2) and PGI(2) also induced AP-2 expression, while PGF(2 alpha) failed to induce this protein. Prostaglandins I 11-14 transcription factor AP-2 alpha Homo sapiens 31-35 11516414-13 2001 The inhibitory effect of indomethacin, but not celecoxib or NS-398, on ectopic activity may suggest that a tonic generation of PGI(2) by COX-1 could contribute to neuropathic pain. Prostaglandins I 127-130 cytochrome c oxidase I, mitochondrial Rattus norvegicus 137-142 11301049-0 2001 Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Prostaglandins I 56-72 interleukin 10 Mus musculus 27-41 11301049-8 2001 Thus the results suggest that PGI(2) and PGE(2) generated simultaneously with cytokines by macrophages treated with zymosan may influence the cytokine production through IP, EP2, and EP4 receptors. Prostaglandins I 30-33 prostaglandin E receptor 2 (subtype EP2) Mus musculus 174-177 11301049-8 2001 Thus the results suggest that PGI(2) and PGE(2) generated simultaneously with cytokines by macrophages treated with zymosan may influence the cytokine production through IP, EP2, and EP4 receptors. Prostaglandins I 30-33 prostaglandin E receptor 4 (subtype EP4) Mus musculus 183-186 11418021-3 2001 PGI(2)and TXA(2)are unstable and convert to stable products 6-keto-PGF(1a)and TXB(2), respectively. Prostaglandins I 0-3 placental growth factor Homo sapiens 67-70 12193539-10 2002 PGE(2), PGF(2alpha), and PGI(2) measurements show that IL-1beta treatment significantly increases progenitor Leydig cell production of these PGs. Prostaglandins I 25-28 interleukin 1 beta Rattus norvegicus 55-63 12042422-7 2002 Secretions of 6-keto PGF(1alpha), a stable derivative of PGI(2), and PGE(2) were induced by physiologic concentrations of Ang II in a time-responsive fashion (P < 0.05). Prostaglandins I 57-60 angiotensinogen Homo sapiens 122-128 11954665-4 2001 The sites and variations of the tissue kallikrein mRNA and protein and of the B2R protein in the human uterus and in fallopian tubes during the luteal phase and in pregnancy coincide with those described for other vasoactive effectors such as nitric oxide, prostacyclins, growth factors, and renin. Prostaglandins I 257-270 kallikrein 1 Homo sapiens 32-49 11546664-2 2001 IL-1 alpha evoked an early (30 min) release of PGI(2) and [(3)H]arachidonate that was blocked by the cytosolic phospholipase A(2)alpha (cPLA(2)alpha) inhibitor arachidonyl trifluoromethyl ketone. Prostaglandins I 47-50 interleukin 1 alpha Homo sapiens 0-10 11546664-2 2001 IL-1 alpha evoked an early (30 min) release of PGI(2) and [(3)H]arachidonate that was blocked by the cytosolic phospholipase A(2)alpha (cPLA(2)alpha) inhibitor arachidonyl trifluoromethyl ketone. Prostaglandins I 47-50 phospholipase A2 group IVA Homo sapiens 136-148 11546664-3 2001 IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. Prostaglandins I 180-183 interleukin 1 alpha Homo sapiens 0-10 11546664-3 2001 IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. Prostaglandins I 180-183 mitogen-activated protein kinase 1 Homo sapiens 34-75 11546664-3 2001 IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. Prostaglandins I 180-183 mitogen-activated protein kinase 3 Homo sapiens 77-83 11546664-3 2001 IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. Prostaglandins I 180-183 cyclin dependent kinase 20 Homo sapiens 85-88 11546664-3 2001 IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. Prostaglandins I 180-183 interferon induced protein 44 Homo sapiens 89-92 11521982-8 2001 There was a significant association between the prevalence of antibodies to CagA and the lowered level of S-PGI (P < 0.0001, Jonckheere-Terpstra trend test). Prostaglandins I 108-111 S100 calcium binding protein A8 Homo sapiens 76-80 11489432-13 2001 We suggest that NO, through cGMP-dependent protein kinases, produces the phosphorylation of a 104-kDa protein that is associated with inhibition in the activity of the COX-1, decreasing PGI(2) synthesis and thereby decreasing coronary PGI(2)-mediated vasodilatation. Prostaglandins I 186-189 prostaglandin-endoperoxide synthase 1 Homo sapiens 168-173 11165876-3 2001 Bovine aortic endothelial cells cultured in Se-deficient media and stimulated with tumor necrosis factor alpha or H2O2 produced significantly less prostacyclin (PGI(2)) and more 15-hydroxyeicosatetraenoic acid, 15-hydroperoxyeicosatetraenoic acid (15-HPETE), and thromboxane than Se-supplemented BAEC. Prostaglandins I 161-164 tumor necrosis factor Bos taurus 83-110 11006279-2 2000 TXAS and prostaglandin I(2) synthase (PGIS), respectively, convert the same substrate, prostaglandin H(2) (PGH(2)), to thromboxane A(2) and prostaglandin I(2), which have opposite biological functions. Prostaglandins I 9-24 prostaglandin I2 synthase Homo sapiens 38-42 10891429-6 2000 Platelet activation by these 2 chemokines appears to involve distinct pathways: SDF-1 inhibited an increase in cyclic adenosine monophosphate (cAMP) following prostaglandin (PG) I(2), while MDC had no effect. Prostaglandins I 159-179 C-X-C motif chemokine ligand 12 Homo sapiens 80-85 11087869-11 2000 We conclude from these observations that PPARdelta, similar to COX-2, is aberrantly expressed in colorectal tumors and that endogenous PPARdelta is transcriptionally responsive to PGI(2). Prostaglandins I 180-183 peroxisome proliferator activated receptor delta Homo sapiens 135-144 11015313-1 2000 The intermolecular cross-regulation mediated by the prostanoid IP-receptor (IP)/EP(1) receptor (EP(1)) agonists PGI(2) and 17 phenyl trinor PGE(2) on TP receptor (TP) signalling within platelets was compared to that which occurs to the individual TPalpha and TPbeta receptors over-expressed in human embryonic kidney (HEK) 293 cells. Prostaglandins I 112-115 prostaglandin I2 receptor Homo sapiens 52-74 11015313-1 2000 The intermolecular cross-regulation mediated by the prostanoid IP-receptor (IP)/EP(1) receptor (EP(1)) agonists PGI(2) and 17 phenyl trinor PGE(2) on TP receptor (TP) signalling within platelets was compared to that which occurs to the individual TPalpha and TPbeta receptors over-expressed in human embryonic kidney (HEK) 293 cells. Prostaglandins I 112-115 prostaglandin E receptor 1 Homo sapiens 80-101 10825288-6 2000 We showed that trefoil factor 3 significantly induces the production of prostaglandin E(2) and prostaglandin I(2) in IEC-18 cells (an intestinal epithelial cell line) in a dose dependent manner. Prostaglandins I 95-110 trefoil factor 3 Rattus norvegicus 15-31 10825288-11 2000 In summary, our results indicate that trefoil factor 3 activates cyclooxygenase-2 in intestinal epithelium to produce prostaglandin I(2) and prostaglandin E(2), which function as survival factors and mediate the cytoprotective action of trefoil factor 3 against oxidant injury. Prostaglandins I 118-133 trefoil factor 3 Rattus norvegicus 38-54 10825288-11 2000 In summary, our results indicate that trefoil factor 3 activates cyclooxygenase-2 in intestinal epithelium to produce prostaglandin I(2) and prostaglandin E(2), which function as survival factors and mediate the cytoprotective action of trefoil factor 3 against oxidant injury. Prostaglandins I 118-133 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 65-81 10825288-11 2000 In summary, our results indicate that trefoil factor 3 activates cyclooxygenase-2 in intestinal epithelium to produce prostaglandin I(2) and prostaglandin E(2), which function as survival factors and mediate the cytoprotective action of trefoil factor 3 against oxidant injury. Prostaglandins I 118-133 trefoil factor 3 Rattus norvegicus 237-253 10446209-5 1999 Agonist (ADP, thrombin, or U46619)-stimulated but not resting platelets adhered to both Cyr61 and Fisp12/mCTGF, and this process was completely inhibited by prostaglandin I(2), which prevents platelet activation. Prostaglandins I 157-172 cellular communication network factor 2 Mus musculus 105-110 10526229-3 1999 However, the addition of TNFalpha brought about a marked increase in the IP mRNA with a lag of about 3 h up to an about 8-fold higher level for 24 h. In addition, the induction of IP was supported by a binding experiment of [(3)H]iloprost (a stable analogue of prostaglandin I(2)). Prostaglandins I 261-276 tumor necrosis factor Mus musculus 25-33 10533800-5 1999 A dissociation between TNF and PGI responses was found for both latex beads and damaged hepatocytes, such that a TNF secretory response was not triggered by either stimulus whereas PGI production was increased for both. Prostaglandins I 31-34 tumor necrosis factor Rattus norvegicus 113-116 10446209-5 1999 Agonist (ADP, thrombin, or U46619)-stimulated but not resting platelets adhered to both Cyr61 and Fisp12/mCTGF, and this process was completely inhibited by prostaglandin I(2), which prevents platelet activation. Prostaglandins I 157-172 coagulation factor II, thrombin Homo sapiens 14-22 10446209-5 1999 Agonist (ADP, thrombin, or U46619)-stimulated but not resting platelets adhered to both Cyr61 and Fisp12/mCTGF, and this process was completely inhibited by prostaglandin I(2), which prevents platelet activation. Prostaglandins I 157-172 cellular communication network factor 1 Homo sapiens 88-93 10446209-5 1999 Agonist (ADP, thrombin, or U46619)-stimulated but not resting platelets adhered to both Cyr61 and Fisp12/mCTGF, and this process was completely inhibited by prostaglandin I(2), which prevents platelet activation. Prostaglandins I 157-172 cellular communication network factor 2 Mus musculus 98-104 10415540-3 1999 Bradykinin appears to function as a signaling molecule by controlling the release of other intracellular modulators, such as prostacyclins and nitric oxide, which also exert beneficial effects on the ischemic myocardium. Prostaglandins I 125-138 kininogen 1 Homo sapiens 0-10 10963682-9 2000 The analysis of arachidonic acid metabolites strongly points to PGE(2) and/or PGI(2) as the likely effectors of COX-2-dependent protection. Prostaglandins I 78-81 prostaglandin G/H synthase 2 Oryctolagus cuniculus 112-117 9069452-3 1997 Ang II stimulated the production of PGI(2), but did not modify that of ET-1. Prostaglandins I 36-39 angiotensinogen Homo sapiens 0-6 8975717-4 1996 The human homolog has been named DSPG3, as it is the third member of the small dermatan sulfate proteoglycan family to be identified and characterized along with biglycan (PG-I) and decorin (PG-II). Prostaglandins I 172-176 epiphycan Homo sapiens 33-38 8674277-0 1996 Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression. Prostaglandins I 16-29 selectin E Homo sapiens 103-113 8963717-5 1996 Adhesion to glass-coated vWF was partially inhibited by heparin and completely inhibited by prostaglandin I(2) and anti-glycoprotein (GP) Ib and anti-GPIIb-IIIa antibodies. Prostaglandins I 92-107 von Willebrand factor Cricetulus griseus 25-28 8963717-6 1996 vWF-dependent adhesion to collagen was not inhibited by heparin, was partially inhibited by anti-GPIIb-IIIa, and was completely inhibited by prostaglandin I(2) and anti-GPIb. Prostaglandins I 141-156 von Willebrand factor Cricetulus griseus 0-3 8631336-11 1996 Hence, PPAR-mediated modulation of gene transcription by prostacyclins may form the basis for their novel role as regulators of gene expression. Prostaglandins I 57-70 peroxisome proliferator activated receptor alpha Rattus norvegicus 7-11 8859931-5 1996 Alteplase (50 x 10(3) IU/ml), a recombinant tissue-type plasminogen activator (t-PA), increased prostaglandin I(2) (PGI(2)) production by aortic endothelial cells from 175.5 +/- 13.8 to 870.8 +/- 131.0 pg/mg cellular protein during a 2-h incubation; other plasminogen activators increased PGI(2) production to a lesser extent. Prostaglandins I 96-111 plasminogen activator, tissue type Homo sapiens 79-83 2287949-2 1990 Three types of PGs with a wide skeletal and extraskeletal distribution, biglycan (PGI), decorin (PGII) and fibromodulin have distinct but homologous core proteins containing leucin-rich sequences. Prostaglandins I 82-85 biglycan Homo sapiens 72-80 21043596-2 1996 Both of the endothelial antiplatelet autacoids prostacyclin (PGI(2)) and nitric oxide (NO) have been demonstrated to inhibit P-selectin expression. Prostaglandins I 61-64 selectin P Homo sapiens 125-135 8595517-6 1995 Plasma TXB2, PGI, LTC4D4E4, and IL-6, expressed as % baseline, were significantly lower in patients receiving IL-1ra than in the placebo group (p < .05), while plasma IL-1 was increased significantly. Prostaglandins I 13-16 interleukin 1 receptor antagonist Homo sapiens 110-116 8595517-6 1995 Plasma TXB2, PGI, LTC4D4E4, and IL-6, expressed as % baseline, were significantly lower in patients receiving IL-1ra than in the placebo group (p < .05), while plasma IL-1 was increased significantly. Prostaglandins I 13-16 interleukin 1 alpha Homo sapiens 110-114 8595517-7 1995 IL-1 may be a necessary mediator of increased circulating PGI, TXB2, LTC4D4E4, and IL-6 levels in patients with sepsis syndrome. Prostaglandins I 58-61 interleukin 1 alpha Homo sapiens 0-4 7766647-2 1995 Proteoglycans in the low molecular mass pool were further resolved by hydrophobic affinity chromatography into two groups identified by cyanogen bromide peptide analysis, amino acid analysis and amino-terminal sequence analysis as PGI (biglycan) and PGII (decorin). Prostaglandins I 231-234 biglycan Bos taurus 236-244 8674277-7 1996 Prostacyclins, its analogs, and mimics significantly reduced E-selectin expression by HDMEC, while the reduction of VCAM-1 expression was much less pronounced. Prostaglandins I 0-13 selectin E Homo sapiens 61-71 8138592-4 1994 The TIS10 gene is a primary response gene encoding a second form of prostaglandin synthase (PGS), the rate-limiting enzyme in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins from arachidonic acid. Prostaglandins I 180-193 prostaglandin-endoperoxide synthase 2 Mus musculus 4-9 8314154-6 1993 RESULTS: The ratio PGI/PGII decreased markedly with increasing severity of the disease. Prostaglandins I 19-22 decorin Homo sapiens 23-27 8314154-13 1993 The decrease of PGI/PGII ratio following atherosclerotic degeneration could play an important role in lipid deposition in arterial wall. Prostaglandins I 16-19 decorin Homo sapiens 20-24 3088690-2 1986 We suggest that prolactin by activating phospholipase A2, induces a release of arachidonic acid which is metabolized by a cyclooxygenase pathway leading to prostaglandins, prostacyclins and thromboxanes, a lipoxygenase pathway leading to hydroperoxides and leukotrienes and an epoxygenase pathway. Prostaglandins I 172-185 prolactin Oryctolagus cuniculus 16-25 2387311-6 1990 A 2.9 kb transcript homologous to a cDNA encoding the human bone small PGI (biglycan) was detected in poly(A)+ RNA isolated from rat VSMCs maintained in vitro as well as within rat thoracic aorta medial tissue. Prostaglandins I 71-74 biglycan Homo sapiens 76-84 1968422-0 1990 Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Prostaglandins I 16-19 biglycan Homo sapiens 21-29 1968422-0 1990 Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Prostaglandins I 16-19 biglycan Homo sapiens 31-34 1968422-1 1990 The genes for PGI (biglycan, BGN) and PGII (decorin, DCN) have been assigned to human chromosomes X and 12 by Southern analysis of a panel of human-rodent somatic cell hybrid DNAs with cDNA probes for these related small proteoglycans. Prostaglandins I 14-17 biglycan Homo sapiens 19-27 1968422-1 1990 The genes for PGI (biglycan, BGN) and PGII (decorin, DCN) have been assigned to human chromosomes X and 12 by Southern analysis of a panel of human-rodent somatic cell hybrid DNAs with cDNA probes for these related small proteoglycans. Prostaglandins I 14-17 biglycan Homo sapiens 29-32 2305591-1 1990 Group I pepsinogen (PG-I) staining was performed in the gastric carcinoma tissues of 75 patients by the peroxidase-antiperoxidase (PAP) method, 44 cases (59%) of which were positive for PG-I, suggesting that they were PG-I-producing gastric carcinomas. Prostaglandins I 186-190 biglycan Homo sapiens 0-24 33940358-0 2021 Socio-geographical evaluation of ecosystem services in an ecotourism destination: PGIS application in Tram Chim National Park, Vietnam. Prostaglandins I 82-86 translocation associated membrane protein 1 Homo sapiens 102-106 2673929-2 1989 When Escherichia coli strains (that are unable to grow on glucose due to the absence of functional zwf (G6PD-) and pgi genes) were transformed with this plasmid (pAC1), they were able to grow on glucose as sole carbon source. Prostaglandins I 115-118 dual specificity phosphatase 2 Homo sapiens 162-166 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 159-162 glucose-6-phosphate isomerase 1 Mus musculus 99-128 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 159-162 glucose-6-phosphate isomerase 1 Mus musculus 133-157 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 159-162 glucose-6-phosphate isomerase Saccharomyces cerevisiae S288C 201-206 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 191-194 glucose-6-phosphate isomerase 1 Mus musculus 99-128 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 191-194 glucose-6-phosphate isomerase 1 Mus musculus 133-157 3352745-5 1988 In our work on the molecular genetics of carbohydrate metabolism we have recently isolated a mouse glucose-6-phosphate isomerase (or phosphoglucose isomerase, PGI) cDNA clone using the yeast PGI gene (PGI 1) as a probe. Prostaglandins I 191-194 glucose-6-phosphate isomerase Saccharomyces cerevisiae S288C 201-206 3317782-3 1987 A significant increase in mean serum PG I above the initial value was found both in unoperated DU patients and in patients after PSV 1 h after insulin injection. Prostaglandins I 37-41 insulin Homo sapiens 143-150 3317782-4 1987 In 29 PSV patients the mean serum PG I showed a paradoxical decrease during the 2nd h after insulin injection, and the mean postvagotomy serum PG I 2 h after insulin injection was significantly (p less than 0.01) lower than the respective preoperative value in the same patients, and the value was close to the basal serum PG I. Prostaglandins I 143-147 insulin Homo sapiens 158-165 3317782-4 1987 In 29 PSV patients the mean serum PG I showed a paradoxical decrease during the 2nd h after insulin injection, and the mean postvagotomy serum PG I 2 h after insulin injection was significantly (p less than 0.01) lower than the respective preoperative value in the same patients, and the value was close to the basal serum PG I. Prostaglandins I 143-147 insulin Homo sapiens 158-165 3317782-5 1987 The low level of serum PG I 2 h after insulin injection in vagotomized patients may reflect the deprivation of the reduced store of PG I in the absence of normal vagal tone. Prostaglandins I 23-27 insulin Homo sapiens 38-45 3317782-6 1987 Both the basal serum PG I and serum PG I response during insulin-induced hypoglycaemia showed an overlap between unoperated and vagotomized DU patients. Prostaglandins I 36-40 insulin Homo sapiens 57-64 3520916-16 1986 C3a and TxB/PGI imbalances are involved in hypovolemic and septic shock. Prostaglandins I 12-15 endogenous retrovirus group K member 2 Homo sapiens 0-11 34817333-16 2021 Serum PGI levels of subjects in the gastric cancer group were significantly lower than those in the healthy group, and the levels of PGII and CA199 were significantly higher than that in the healthy group, with statistical significance (P <0.05). Prostaglandins I 6-9 progastricsin Homo sapiens 133-137 2810910-2 1989 In patients with gastric cancer, serum PG-I tended to decrease but PG-II stayed normal level, resulting in low PG-I/PG-II ratio. Prostaglandins I 39-43 progastricsin Homo sapiens 116-121 2810910-2 1989 In patients with gastric cancer, serum PG-I tended to decrease but PG-II stayed normal level, resulting in low PG-I/PG-II ratio. Prostaglandins I 67-71 progastricsin Homo sapiens 116-121 2901939-3 1988 However, serum PG I levels were significantly higher (P less than 0.01) in the hyperparathyroid patients with hypergastrinemia (PGI median 192, range 75-864 ng/ml) than in those with normogastrinemia (PGI median 75, range 35-139 ng/ml). Prostaglandins I 128-131 biglycan Homo sapiens 15-19 2901939-3 1988 However, serum PG I levels were significantly higher (P less than 0.01) in the hyperparathyroid patients with hypergastrinemia (PGI median 192, range 75-864 ng/ml) than in those with normogastrinemia (PGI median 75, range 35-139 ng/ml). Prostaglandins I 201-204 biglycan Homo sapiens 15-19 3088690-2 1986 We suggest that prolactin by activating phospholipase A2, induces a release of arachidonic acid which is metabolized by a cyclooxygenase pathway leading to prostaglandins, prostacyclins and thromboxanes, a lipoxygenase pathway leading to hydroperoxides and leukotrienes and an epoxygenase pathway. Prostaglandins I 172-185 phospholipase A2 Oryctolagus cuniculus 40-56 3884360-0 1985 Hepatoprotective effects of prostacyclins on CCl4-induced liver injury in rats. Prostaglandins I 28-41 C-C motif chemokine ligand 4 Rattus norvegicus 45-49 6996017-5 1980 These findings strengthen the view of a direct involvement of prostacyclins in renin release mechanisms. Prostaglandins I 62-75 renin Rattus norvegicus 79-84 33430456-12 2021 CONCLUSIONS: Serum PGII levels depend in part on an interaction between H. pylori and host miRNA genotypes, which may interfere with the cut-off of PGI/PGII ratio used to identify persons at risk of gastric cancer. Prostaglandins I 19-22 progastricsin Homo sapiens 152-156 6761139-6 1980 We postulate from our model that prostaglandins E and prostacyclins are involved in the mechanism of kidney production of erythropoietin as well as the activation of the Ep-responsive cell (ERC) compartment. Prostaglandins I 54-67 erythropoietin Mus musculus 122-136 31646814-9 2019 After therapy with PG I, the G17 and PG II levels increased. Prostaglandins I 19-23 progastricsin Homo sapiens 37-42 32133049-0 2020 Correction: AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. Prostaglandins I 16-19 mitogen-activated protein kinase 1 Homo sapiens 51-55 32133049-0 2020 Correction: AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. Prostaglandins I 16-19 mitogen-activated protein kinase 1 Homo sapiens 56-59 29875848-12 2018 A positive correlation was reported between serum levels of PGI; PGII; PGI/PGII; G-17; PMNs grade and Immunopathological status of the gastroduodenal mucosa of H. pylori Infected patients. Prostaglandins I 60-63 progastricsin Homo sapiens 75-79 29995453-9 2018 The PGI hits are effective against trypanosomatid PGIs, with IC50 values in the micromolar range, and also against the human homologous enzyme. Prostaglandins I 50-54 glucose-6-phosphate isomerase Homo sapiens 4-7 28451639-12 2017 These results revealed that microglia-derived TNFalpha induced COX2 and PGIS expression in spinal endothelial cells and that endothelial PGI2 played a critical role in neuropathic pain via neuronal IP receptor. Prostaglandins I 72-76 tumor necrosis factor Rattus norvegicus 46-54 28436254-14 2017 For both Hp-positive patients and Hp-negative patients according to OLGA system, PGI/PGII level correlated inversely with the rising stage (p = .022; p = .028). Prostaglandins I 81-84 progastricsin Homo sapiens 85-89 29244926-10 2016 When ELISA amount pepsinogen patients showed significant increase in serum levels of PG-I relative to the control group at 33.4%, PG-II - 52%. Prostaglandins I 85-89 decorin Homo sapiens 130-135 26108557-6 2016 In addition, the multifaceted role of glucose-6-phosphate isomerase (PGI) was confirmed, based on a significant correlation between PGI activity and the percentage of G2/M-phase cells. Prostaglandins I 69-72 glucose-6-phosphate isomerase Cricetulus griseus 38-67 26108557-6 2016 In addition, the multifaceted role of glucose-6-phosphate isomerase (PGI) was confirmed, based on a significant correlation between PGI activity and the percentage of G2/M-phase cells. Prostaglandins I 132-135 glucose-6-phosphate isomerase Cricetulus griseus 38-67 26936801-1 2016 Phosphoglucose isomerase/autocrine motility factor (PGI/AMF) is secreted by tumors and influences tumor growth and metastasis. Prostaglandins I 52-55 glucose-6-phosphate isomerase Homo sapiens 0-24 26936801-9 2016 The silencing of PGI/AMF decreased the levels of phosphorylated Akt (-71.9%, P<0.001) compared with the scrambled siRNA, as well as the levels of the stemness marker, SOX2 (-61.7%, P<0.01). Prostaglandins I 17-20 AKT serine/threonine kinase 1 Homo sapiens 64-67 26936801-9 2016 The silencing of PGI/AMF decreased the levels of phosphorylated Akt (-71.9%, P<0.001) compared with the scrambled siRNA, as well as the levels of the stemness marker, SOX2 (-61.7%, P<0.01). Prostaglandins I 17-20 SRY-box transcription factor 2 Homo sapiens 170-174 24385109-0 2014 High-density lipoprotein induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through sphingosine kinase-2. Prostaglandins I 65-80 sphingosine kinase 2 Homo sapiens 120-140 23628005-10 2015 In conclusion, we demonstrated that BPS or adv-COX-1/PGIS increases PGI2 levels through iNOS expression and peroxynitrite production, via CREB protein phosphorylation; thereby aggravating DOX-mediated cardiotoxicity. Prostaglandins I 53-57 cytochrome c oxidase I, mitochondrial Mus musculus 47-52 23628005-10 2015 In conclusion, we demonstrated that BPS or adv-COX-1/PGIS increases PGI2 levels through iNOS expression and peroxynitrite production, via CREB protein phosphorylation; thereby aggravating DOX-mediated cardiotoxicity. Prostaglandins I 53-57 prostaglandin I receptor (IP) Mus musculus 68-72 23628005-10 2015 In conclusion, we demonstrated that BPS or adv-COX-1/PGIS increases PGI2 levels through iNOS expression and peroxynitrite production, via CREB protein phosphorylation; thereby aggravating DOX-mediated cardiotoxicity. Prostaglandins I 53-57 nitric oxide synthase 2, inducible Mus musculus 88-92 23628005-10 2015 In conclusion, we demonstrated that BPS or adv-COX-1/PGIS increases PGI2 levels through iNOS expression and peroxynitrite production, via CREB protein phosphorylation; thereby aggravating DOX-mediated cardiotoxicity. Prostaglandins I 53-57 cAMP responsive element binding protein 1 Mus musculus 138-142 23628005-4 2015 For this reason, we stimulated endogenous PGI2 production using bicistronic COX-1/PGIS gene transfer and BPS supplementation, and investigated the effects on DOX-induced cardiomyopathy. Prostaglandins I 82-86 prostaglandin I receptor (IP) Mus musculus 42-46 25195038-9 2014 Multivariate analysis identified Dicer1 as an independent prognostic factor in PGI-DLBCL. Prostaglandins I 79-82 dicer 1, ribonuclease III Homo sapiens 33-39 23127498-8 2013 These results demonstrate explicitly that in mouse arteries celecoxib not only inhibits COX-1-mediated synthesis of PGI(2) and probably some other prostanoids, but also causes a reduction in vessel contractility that is independent of either COX-2 or COX-1, leading to an inhibition of COX-1-mediated endothelium-dependent contraction with an IC(50) value far below that of it considered for COX-1 . Prostaglandins I 116-119 cytochrome c oxidase I, mitochondrial Mus musculus 88-93 23602873-0 2013 Resistant to thrombosis, induced stroke and heart arrest by incorporation of a single gene of PGI2-synthesizing COX-1-PGIS in vivo: Implication against human heart disease. Prostaglandins I 118-122 mitochondrially encoded cytochrome c oxidase I Homo sapiens 112-117 23400934-7 2013 Overexpression of BubR1 was observed in the majority of PGI-DLBCL patients. Prostaglandins I 56-59 BUB1 mitotic checkpoint serine/threonine kinase B Homo sapiens 18-23 24337227-11 2014 In conclusion, the results from the current study suggest that H(2)S enhances hypoxia-induced cell proliferation through the upregulation of COX-2/PGI(2), as opposed to ROS. Prostaglandins I 147-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 23567270-6 2013 Purified, recombinant PGIS showed a half-maximal nitration by 10 muM 3-morpholino sydnonimine (Sin-1) which increased in the presence of bicarbonate, and was only marginally induced by freely diffusing NO2-radicals generated by a peroxidase/nitrite/hydrogen peroxide system. Prostaglandins I 22-26 MAPK associated protein 1 Homo sapiens 95-100 21722977-3 2013 METHODS: Here, we have engineered a novel adipose tissue-derived cell that constantly produces PGI(2,) through transfecting of an engineered cDNA of a hybrid enzyme (human COX-1-10-aa-PGIS) which has superior triple catalytic functions in directly converting arachidonic acid into PGI(2). Prostaglandins I 95-98 mitochondrially encoded cytochrome c oxidase I Homo sapiens 172-177 21722977-3 2013 METHODS: Here, we have engineered a novel adipose tissue-derived cell that constantly produces PGI(2,) through transfecting of an engineered cDNA of a hybrid enzyme (human COX-1-10-aa-PGIS) which has superior triple catalytic functions in directly converting arachidonic acid into PGI(2). Prostaglandins I 95-98 prostaglandin I2 synthase Homo sapiens 184-188 21722977-3 2013 METHODS: Here, we have engineered a novel adipose tissue-derived cell that constantly produces PGI(2,) through transfecting of an engineered cDNA of a hybrid enzyme (human COX-1-10-aa-PGIS) which has superior triple catalytic functions in directly converting arachidonic acid into PGI(2). Prostaglandins I 95-98 prostaglandin I receptor (IP) Mus musculus 281-287 23276664-2 2013 We have examined the hypothesis that COX-2 activity contributes more to vasodilation in hyperglycemic animals than in healthy counterparts, and that COX-2 derived vasodilatory prostaglandins (PGI(2) and PGE(2)) are responsible for this effect. Prostaglandins I 192-195 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 149-154 22727878-5 2012 This review discusses emerging evidence regarding the contribution of PPARdelta activation to vasoprotective and regenerative functions of PGI(2) and stable analogs of PGI(2). Prostaglandins I 139-142 peroxisome proliferator activated receptor delta Homo sapiens 70-79 23326145-10 2012 Lower plasma PGI/PG II ratio was associated with higher risks of atrophy and gastric cancer. Prostaglandins I 13-16 progastricsin Homo sapiens 17-22 23039317-11 2012 The calculated conformational energies of these structures are unusually stable relative to all others, with energies significantly lower than the PGI/PGII conformations characteristic of polyglycine structures in solution and in the crystalline form, where intermolecular H-bonds play a role. Prostaglandins I 147-150 progastricsin Homo sapiens 151-155 22262921-10 2012 Urinary PGI-M, but not PGE-M, was negatively correlated with circulating levels of fibroblast growth factor 2 and angiogenin. Prostaglandins I 8-11 fibroblast growth factor 2 Homo sapiens 83-109 22746401-6 2012 COX-2 activity was further assessed by urine 2,3-dinor-6-keto PGF(1alpha) level, a major metabolite of prostacyclin I(2) (PGI(2)). Prostaglandins I 122-125 cytochrome c oxidase II, mitochondrial Mus musculus 0-5 22505639-10 2012 The assessment of systemic generation of thromboxane A(2) (TXA(2)) and prostaglandin I(2) (PGI(2)) revealed significant decrease in the production of PGI(2) in ApoE(-/-)/Kit(W-sh/W-sh) mice with no change in TXA(2). Prostaglandins I 91-94 apolipoprotein E Mus musculus 160-164 22505639-10 2012 The assessment of systemic generation of thromboxane A(2) (TXA(2)) and prostaglandin I(2) (PGI(2)) revealed significant decrease in the production of PGI(2) in ApoE(-/-)/Kit(W-sh/W-sh) mice with no change in TXA(2). Prostaglandins I 150-153 apolipoprotein E Mus musculus 160-164 22622660-7 2012 Moreover, PUFA are incorporated in breast cancer lipid rafts with different specificity for the phospholipid moiety, in particular PUFA are incorporated in PI, PS, and PC phospholipids that may be relevant to the formation of PUFA metabolites (prostaglandins, prostacyclins, leukotrienes, resolvines, and protectines) of phospholipids deriving second messengers and signal transduction activation. Prostaglandins I 260-273 pumilio RNA binding family member 3 Homo sapiens 10-14 22622660-7 2012 Moreover, PUFA are incorporated in breast cancer lipid rafts with different specificity for the phospholipid moiety, in particular PUFA are incorporated in PI, PS, and PC phospholipids that may be relevant to the formation of PUFA metabolites (prostaglandins, prostacyclins, leukotrienes, resolvines, and protectines) of phospholipids deriving second messengers and signal transduction activation. Prostaglandins I 260-273 pumilio RNA binding family member 3 Homo sapiens 131-135 22622660-7 2012 Moreover, PUFA are incorporated in breast cancer lipid rafts with different specificity for the phospholipid moiety, in particular PUFA are incorporated in PI, PS, and PC phospholipids that may be relevant to the formation of PUFA metabolites (prostaglandins, prostacyclins, leukotrienes, resolvines, and protectines) of phospholipids deriving second messengers and signal transduction activation. Prostaglandins I 260-273 pumilio RNA binding family member 3 Homo sapiens 131-135 22262921-2 2012 Thus, a profound inhibition of COX-2-dependent PGI(2) might be associated with changes in circulating markers of angiogenesis. Prostaglandins I 47-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 22390933-4 2012 Furthermore, SR-B1 was found to be involved in HDL induced up-regulation of COX-2 and PGI(2). Prostaglandins I 86-89 scavenger receptor class B member 1 Homo sapiens 13-18 22410675-1 2012 Five primary prostanoids are synthesized by the cyclooxygenase enzymes, COX-1 and COX-2: the prostaglandins PGE(2), PGF(2alpha), PGI(2), PGD(2) and thromboxane A2. Prostaglandins I 129-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 22262921-10 2012 Urinary PGI-M, but not PGE-M, was negatively correlated with circulating levels of fibroblast growth factor 2 and angiogenin. Prostaglandins I 8-11 angiogenin Homo sapiens 114-124 21085923-4 2011 To this end, we investigated the in vitro effects of PGI(2) analogues on the expression of Th1-related chemokine interferon-gamma-inducible protein-10 (IP-10/CXCL10) and Th2-related chemokine macrophage-derived chemokine (MDC/CCL22) in human monocytes. Prostaglandins I 53-56 negative elongation factor complex member C/D Homo sapiens 91-94 21769544-8 2011 These findings strongly support the hypothesis of a link between iNOS-dependent NO overproduction and LPS-induced cell loss with a selective protective role allotted to COX-2 and deriving prostacyclins. Prostaglandins I 188-201 nitric oxide synthase 2, inducible Mus musculus 65-69 22346776-5 2011 RESULTS: Both PGE(2) and PGI(2) productions were almost completely inhibited by the depletion of COX-2. Prostaglandins I 25-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 21474648-8 2011 Synthetic PGF(2alpha) and PGI(2) enhanced Th17 cell differentiation of COX-2(-/-) CD4(+) T cells in vitro. Prostaglandins I 26-29 cytochrome c oxidase II, mitochondrial Mus musculus 71-76 21400214-0 2011 Prostaglandin I(2) analogues suppress TNF-alpha expression in human monocytes via mitogen-activated protein kinase pathway. Prostaglandins I 0-15 tumor necrosis factor Homo sapiens 38-47 21255012-2 2011 We have shown that histamine, acting via H1 receptors (H1R), synergizes lipopolysaccharide (LPS)-induced production of prostaglandin I(2) (PGI(2)), PGE(2) and interleukin-6 (IL-6) by endothelial cells. Prostaglandins I 119-134 histamine receptor H1 Homo sapiens 41-53 21255012-2 2011 We have shown that histamine, acting via H1 receptors (H1R), synergizes lipopolysaccharide (LPS)-induced production of prostaglandin I(2) (PGI(2)), PGE(2) and interleukin-6 (IL-6) by endothelial cells. Prostaglandins I 119-134 histamine receptor H1 Homo sapiens 55-58 21255012-2 2011 We have shown that histamine, acting via H1 receptors (H1R), synergizes lipopolysaccharide (LPS)-induced production of prostaglandin I(2) (PGI(2)), PGE(2) and interleukin-6 (IL-6) by endothelial cells. Prostaglandins I 139-142 histamine receptor H1 Homo sapiens 41-53 21255012-2 2011 We have shown that histamine, acting via H1 receptors (H1R), synergizes lipopolysaccharide (LPS)-induced production of prostaglandin I(2) (PGI(2)), PGE(2) and interleukin-6 (IL-6) by endothelial cells. Prostaglandins I 139-142 histamine receptor H1 Homo sapiens 55-58 21255012-12 2011 Histamine-induced enhancement of the synthesis of PGI(2), PGE(2) and IL-6 by LPS-primed HCAEC was completely blocked by an H1R antagonist. Prostaglandins I 50-53 histamine receptor H1 Homo sapiens 123-126 23300697-5 2012 We revealed that, in the mouse heart, HEXIM1 is highly expressed in the early postnatal period and its expression is gradually decreased, and that prostaglandin I(2), a therapeutic drug for PAH, increases HEXIM1 levels in cardiomyocytes. Prostaglandins I 147-162 hexamethylene bis-acetamide inducible 1 Mus musculus 38-44 23300697-5 2012 We revealed that, in the mouse heart, HEXIM1 is highly expressed in the early postnatal period and its expression is gradually decreased, and that prostaglandin I(2), a therapeutic drug for PAH, increases HEXIM1 levels in cardiomyocytes. Prostaglandins I 147-162 hexamethylene bis-acetamide inducible 1 Mus musculus 205-211 21085923-4 2011 To this end, we investigated the in vitro effects of PGI(2) analogues on the expression of Th1-related chemokine interferon-gamma-inducible protein-10 (IP-10/CXCL10) and Th2-related chemokine macrophage-derived chemokine (MDC/CCL22) in human monocytes. Prostaglandins I 53-56 C-X-C motif chemokine ligand 10 Homo sapiens 152-157 21085923-4 2011 To this end, we investigated the in vitro effects of PGI(2) analogues on the expression of Th1-related chemokine interferon-gamma-inducible protein-10 (IP-10/CXCL10) and Th2-related chemokine macrophage-derived chemokine (MDC/CCL22) in human monocytes. Prostaglandins I 53-56 C-X-C motif chemokine ligand 10 Homo sapiens 158-164 20457271-7 2010 We conclude that stable PGI(2) mimetics may be highly specific inhibitors of p27(kip1)-dependent VSMC proliferation after vascular injury. Prostaglandins I 24-27 zinc ribbon domain containing 2 Homo sapiens 77-80 20457271-7 2010 We conclude that stable PGI(2) mimetics may be highly specific inhibitors of p27(kip1)-dependent VSMC proliferation after vascular injury. Prostaglandins I 24-27 cyclin dependent kinase inhibitor 1B Homo sapiens 81-85 20392830-1 2010 We recently described a novel GnRH receptor signaling pathway mediated by the prostaglandins (PGs) F(2alpha) and PGI(2), which acts through an autocrine/paracrine modality to limit autoregulation of the GnRH receptor and inhibit LH but not FSH release. Prostaglandins I 113-116 gonadotropin releasing hormone receptor Mus musculus 30-43 20399788-1 2010 Cyclooxygenase-1 and -2 are rate-limiting enzymes in the formation of a wide array of bioactive lipid mediators collectively known as prostanoids (prostaglandins, prostacyclins, and thromboxanes). Prostaglandins I 163-176 prostaglandin-endoperoxide synthase 1 Mus musculus 0-23 20392830-1 2010 We recently described a novel GnRH receptor signaling pathway mediated by the prostaglandins (PGs) F(2alpha) and PGI(2), which acts through an autocrine/paracrine modality to limit autoregulation of the GnRH receptor and inhibit LH but not FSH release. Prostaglandins I 113-116 gonadotropin releasing hormone receptor Mus musculus 203-216 20107114-4 2010 Acute infusion of the vasoconstrictor ANG II increases COX-2-dependent PGE(2) and PGI(2). Prostaglandins I 82-85 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 38-44 19361808-3 2010 We have examined whether gene transfer-mediated overexpression of COX-1 in grafted veins (1) increases PGI(2) and cyclic AMP (cAMP) production, (2) leads to vasodilation and improved local blood flow in the presence of hypercholesterolemia, and (3) reduces neointima formation. Prostaglandins I 103-106 cytochrome c oxidase subunit I Oryctolagus cuniculus 66-71 20445242-6 2010 The crystal structure of Mtb PGI was observed to be rather more similar to human PGI than other nonbacterial PGIs, with only a few differences being detected in the loops, arm and hook regions of the human and Mtb PGIs, suggesting that the M. tuberculosis enzyme uses the same enzyme mechanism. Prostaglandins I 109-113 glucose-6-phosphate isomerase Homo sapiens 29-32 20107114-4 2010 Acute infusion of the vasoconstrictor ANG II increases COX-2-dependent PGE(2) and PGI(2). Prostaglandins I 82-85 cytochrome c oxidase II, mitochondrial Mus musculus 55-60 20107114-13 2010 Excretion of 6-keto-PGF(2alpha), the metabolite of PGI(2), was increased by ANG II infusion, whereas excretion of TxB(2), the stable metabolite of TxA(2), was not changed. Prostaglandins I 51-54 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 76-82 19879866-2 2010 Prescription of high doses of aspirin and selective cyclooxygenase-2 inhibitors is reported to increase cardiovascular events through suppression of the vasodilative prostanoid prostaglandin I(2) in endothelium. Prostaglandins I 177-192 prostaglandin-endoperoxide synthase 2 Mus musculus 52-68 19447019-9 2010 In summary, these results suggest that L-carnitine attenuates Ang II-induced effects (including NADPH oxidase activation, sphingosine-1-phosphate generation and cell proliferation) in part through PGI(2) and PPAR alpha-signaling pathways. Prostaglandins I 197-200 angiotensinogen Rattus norvegicus 62-68 20082561-4 2010 Inhibition of p42/p44(mapk) or src kinases prevented the increase in PGI(2) and cAMP observed in response to BK or IGF-1, indicating a role for these kinases in the regulation of cPLA(2) activity in the VSMC. Prostaglandins I 69-72 cyclin dependent kinase like 1 Homo sapiens 14-17 20082561-4 2010 Inhibition of p42/p44(mapk) or src kinases prevented the increase in PGI(2) and cAMP observed in response to BK or IGF-1, indicating a role for these kinases in the regulation of cPLA(2) activity in the VSMC. Prostaglandins I 69-72 interferon induced protein 44 Homo sapiens 18-27 20082561-4 2010 Inhibition of p42/p44(mapk) or src kinases prevented the increase in PGI(2) and cAMP observed in response to BK or IGF-1, indicating a role for these kinases in the regulation of cPLA(2) activity in the VSMC. Prostaglandins I 69-72 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 31-34 20082561-4 2010 Inhibition of p42/p44(mapk) or src kinases prevented the increase in PGI(2) and cAMP observed in response to BK or IGF-1, indicating a role for these kinases in the regulation of cPLA(2) activity in the VSMC. Prostaglandins I 69-72 kininogen 1 Homo sapiens 109-111 20082561-4 2010 Inhibition of p42/p44(mapk) or src kinases prevented the increase in PGI(2) and cAMP observed in response to BK or IGF-1, indicating a role for these kinases in the regulation of cPLA(2) activity in the VSMC. Prostaglandins I 69-72 insulin like growth factor 1 Homo sapiens 115-120 19952427-6 2009 CONCLUSIONS: The decreases in COX-2 and PGI(2) synthase expression in severe PIH placentas may be causal factors in the disruption of the PGI(2)-thromboxane A(2) (TXA(2)) balance in favor of TXA(2). Prostaglandins I 40-43 pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included) Homo sapiens 77-80 19464432-2 2009 COX-1 is a constitutive enzyme while the expression of COX-2 is highly stimulated in the event of inflammatory processes, leading to the production of large amounts of prostaglandins (PGs), in particular PGE(2) and PGI(2), which are pro-inflammatory mediators. Prostaglandins I 215-218 mitochondrially encoded cytochrome c oxidase I Homo sapiens 0-5 20122226-11 2010 CONCLUSION: The binding pockets in PGDS, PGES, PGFS and PGIS are unique and do not share significant commonality which can be characterized as a PGH2 binding site. Prostaglandins I 56-60 prostaglandin D2 synthase Homo sapiens 35-39 19201774-8 2009 Separately, PGE(2) and PGI(2) induced cell proliferation and extracellular signal-regulated kinase (ERK) activation in HSCs. Prostaglandins I 23-26 Eph receptor B1 Rattus norvegicus 61-98 19201774-8 2009 Separately, PGE(2) and PGI(2) induced cell proliferation and extracellular signal-regulated kinase (ERK) activation in HSCs. Prostaglandins I 23-26 Eph receptor B1 Rattus norvegicus 100-103 19739103-7 2009 The increase of COX-2 expression by thrombin was functionally linked to release of PGE(2) and PGI(2) but not thromboxane A(2) into macrophage culture medium. Prostaglandins I 94-97 prostaglandin-endoperoxide synthase 2 Mus musculus 16-21 19739103-7 2009 The increase of COX-2 expression by thrombin was functionally linked to release of PGE(2) and PGI(2) but not thromboxane A(2) into macrophage culture medium. Prostaglandins I 94-97 coagulation factor II Mus musculus 36-44 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Prostaglandins I 168-171 C-reactive protein Homo sapiens 61-64 19464432-2 2009 COX-1 is a constitutive enzyme while the expression of COX-2 is highly stimulated in the event of inflammatory processes, leading to the production of large amounts of prostaglandins (PGs), in particular PGE(2) and PGI(2), which are pro-inflammatory mediators. Prostaglandins I 215-218 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 19207291-5 2009 Coexpression of PGHS-1 with cDNAs encoding mouse prostaglandin I synthase and thromboxane A synthase, and with Trypanosoma brucei genomic DNA encoding prostaglandin F synthase in AA-supplemented yeast cultures resulted in production of the corresponding prostanoids, prostaglandin I(2), thromboxane A(2) and prostaglandin F(2alpha). Prostaglandins I 49-64 prostaglandin-endoperoxide synthase 1 Mus musculus 16-22 18952694-9 2009 The COX-2 induction was accompanied by an increase in PGE(2) (prostaglandin E(2)) and PGI(2) (prostaglandin I(2)) release in the culture medium (approximately 2.5-fold) but not with an increase in TxA(2) (thromboxane A(2)) release. Prostaglandins I 94-109 prostaglandin-endoperoxide synthase 2 Homo sapiens 4-9 19084534-4 2009 COX-2 expression was confirmed by immunoblotting and by increased levels of PGE(2) and PGI(2) in myocardium. Prostaglandins I 87-90 cytochrome c oxidase II, mitochondrial Mus musculus 0-5 19577709-7 2009 Absence of COX-2 in vitro led to enhanced contractility of PASMC after exposure to hypoxia, which could be attenuated by iloprost, a prostaglandin I(2) analog. Prostaglandins I 133-148 prostaglandin-endoperoxide synthase 2 Homo sapiens 11-16 18458045-4 2008 13-cis-RA increased the release of prostaglandin I(2) (PGI(2)), both spontaneous and thrombin-induced, in terms of 6-oxo-PGF(1alpha) analyzed by enzyme-immunoassay. Prostaglandins I 35-50 coagulation factor II, thrombin Homo sapiens 85-93 18514659-8 2009 Stable urinary metabolites of PGI(2) and TXA(2), which were markedly increased in the ApoE(-/-)/COX-1(+/+) were reduced by disruption of COX-1. Prostaglandins I 30-33 apolipoprotein E Mus musculus 86-90 18514659-8 2009 Stable urinary metabolites of PGI(2) and TXA(2), which were markedly increased in the ApoE(-/-)/COX-1(+/+) were reduced by disruption of COX-1. Prostaglandins I 30-33 prostaglandin-endoperoxide synthase 1 Mus musculus 96-101 18514659-8 2009 Stable urinary metabolites of PGI(2) and TXA(2), which were markedly increased in the ApoE(-/-)/COX-1(+/+) were reduced by disruption of COX-1. Prostaglandins I 30-33 prostaglandin-endoperoxide synthase 1 Mus musculus 137-142 20641717-13 2004 PGI is a small molecule that is a potent inhibitor of NAALADase, with a Ki of 9.0 nM, whereas IRDye78 had a Ki of 500 nM (7). Prostaglandins I 0-3 folate hydrolase 1 Homo sapiens 54-63 18458045-4 2008 13-cis-RA increased the release of prostaglandin I(2) (PGI(2)), both spontaneous and thrombin-induced, in terms of 6-oxo-PGF(1alpha) analyzed by enzyme-immunoassay. Prostaglandins I 55-58 coagulation factor II, thrombin Homo sapiens 85-93 18458045-5 2008 Coincubation with 13-cis-RA and interleukin-1beta resulted in a synergic increase in the release of PGI(2). Prostaglandins I 100-103 interleukin 1 beta Homo sapiens 32-49 18385449-9 2008 Addition of exogenous PGI(2) or CGRP restored the MNA-induced gastroprotection in rats treated with COX-1 and COX-2 inhibitors or in those with capsaicin denervation. Prostaglandins I 22-25 cytochrome c oxidase II, mitochondrial Rattus norvegicus 110-115 18058808-6 2008 18.PGDH and 18.K-Ras(V12).PGDH cells had 10(4)-fold increases in PGDH activity with decreased PGE(2) and PGI(2) levels, COX-2 and mPGES-1 expression and proliferation rates. Prostaglandins I 105-108 15-hydroxyprostaglandin dehydrogenase Rattus norvegicus 26-30 18058808-6 2008 18.PGDH and 18.K-Ras(V12).PGDH cells had 10(4)-fold increases in PGDH activity with decreased PGE(2) and PGI(2) levels, COX-2 and mPGES-1 expression and proliferation rates. Prostaglandins I 105-108 15-hydroxyprostaglandin dehydrogenase Rattus norvegicus 26-30 18058808-5 2008 18.K-Ras(V12) cells exhibited increased phosphorylation of MAP kinases and CREB, proliferation rates, COX-2 and microsomal prostaglandin E synthase (mPGES)-1 expression and PGE(2) and PGI(2) levels. Prostaglandins I 184-187 KRAS proto-oncogene, GTPase Rattus norvegicus 3-12 17321146-10 2007 The cells cultured on PF or PFP were able to produce prostaglandin I(2) or tissue-plasminogen activator in response to thrombin. Prostaglandins I 53-68 perforin 1 Homo sapiens 28-31 18646550-5 2008 CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism. Prostaglandins I 219-232 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-3 18285567-8 2008 Deletion of mPGES-1 also depressed urinary PGE-M, whereas it augmented excretion of PGD(2) and PGI(2) metabolites, reflecting rediversion of the accumulated PGH(2) substrate in the double knockouts. Prostaglandins I 95-98 prostaglandin E synthase Mus musculus 12-19 18391113-9 2008 Treatment of COX-2-deficient PASMCs with iloprost, a prostaglandin I(2) analog, and prostaglandin E(2) abrogated the potent contractile response to hypoxia and restored the wild-type phenotype. Prostaglandins I 53-68 prostaglandin-endoperoxide synthase 2 Mus musculus 13-18 18391113-11 2008 COX-2-deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2-derived prostaglandin I(2) or prostaglandin E(2). Prostaglandins I 148-163 prostaglandin-endoperoxide synthase 2 Mus musculus 0-5 18391113-11 2008 COX-2-deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2-derived prostaglandin I(2) or prostaglandin E(2). Prostaglandins I 148-163 prostaglandin-endoperoxide synthase 2 Mus musculus 134-139 18419601-6 2008 Importantly, spinal cords and primary spinal cord cells derived from mPGES-1-deficient mice showed a redirection of the PGE(2) synthesis to PGD(2), PGF(2alpha) and 6-keto-PGF(1alpha) (stable metabolite of PGI(2)). Prostaglandins I 205-208 prostaglandin E synthase Mus musculus 69-76 18209033-6 2008 Specifically in response to TNF-alpha, TGF-beta, and LPS, protein expression of cyclooxygenase (COX)-2 and downstream PGE synthase was up-regulated with coordinate kinetics, whereas COX-1 and PGIS were constitutively expressed. Prostaglandins I 192-196 tumor necrosis factor Homo sapiens 28-37 18209033-6 2008 Specifically in response to TNF-alpha, TGF-beta, and LPS, protein expression of cyclooxygenase (COX)-2 and downstream PGE synthase was up-regulated with coordinate kinetics, whereas COX-1 and PGIS were constitutively expressed. Prostaglandins I 192-196 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-102 18025237-2 2007 In this study, we investigated the effects of histamine on the expression of COX-1 and COX-2 and determined their contribution to the production of PGE(2), prostacyclin (PGI(2)), and thromboxane A(2) in human coronary artery endothelial cells (HCAEC). Prostaglandins I 170-173 mitochondrially encoded cytochrome c oxidase I Homo sapiens 77-82 17321146-10 2007 The cells cultured on PF or PFP were able to produce prostaglandin I(2) or tissue-plasminogen activator in response to thrombin. Prostaglandins I 53-68 coagulation factor II, thrombin Homo sapiens 119-127 17493609-0 2007 Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Prostaglandins I 26-29 Rap guanine nucleotide exchange factor 3 Homo sapiens 86-91 17522345-1 2007 We recently demonstrated that calcitonin gene-related peptide (CGRP) released from sensory neurons reduces spinal cord injury (SCI) by inhibiting neutrophil activation through an increase in the endothelial production of prostacyclin (PGI(2)). Prostaglandins I 235-238 calcitonin-related polypeptide alpha Rattus norvegicus 30-61 17522345-1 2007 We recently demonstrated that calcitonin gene-related peptide (CGRP) released from sensory neurons reduces spinal cord injury (SCI) by inhibiting neutrophil activation through an increase in the endothelial production of prostacyclin (PGI(2)). Prostaglandins I 235-238 calcitonin-related polypeptide alpha Rattus norvegicus 63-67 17643885-7 2007 Moreover, when placed on an atherogenic diet, COX-2 deficiency resulted in (i) increased lipid deposition in the aorta, (ii) a further dramatic imbalance in circulating eicosanoids, i.e. decreased serum PGI(2) coupled with increased PGE(2) and TXB(2), and (iii) a marked elevation of pro-inflammatory cytokines, TNF and IL-6. Prostaglandins I 203-206 cytochrome c oxidase II, mitochondrial Mus musculus 46-51 17493609-0 2007 Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Prostaglandins I 26-29 RAP1A, member of RAS oncogene family Homo sapiens 92-96 17493609-0 2007 Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Prostaglandins I 26-29 Rac family small GTPase 1 Homo sapiens 107-110 17485013-9 2007 Aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiated the contractile response of gastroepiploic artery to adrenergic stimulation by inhibiting COX-2-derived PGI(2). Prostaglandins I 192-195 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 17403097-2 2007 OBJECTIVE: To study the influence of cyclooxygenase (COX) and PGE synthase (PGES) isoenzyme expression on PGE(2) and PGI(2) biosynthesis in vascular smooth muscle cells (VSMC) in culture. Prostaglandins I 117-120 prostaglandin E synthase Homo sapiens 62-74 17403097-2 2007 OBJECTIVE: To study the influence of cyclooxygenase (COX) and PGE synthase (PGES) isoenzyme expression on PGE(2) and PGI(2) biosynthesis in vascular smooth muscle cells (VSMC) in culture. Prostaglandins I 117-120 prostaglandin E synthase Homo sapiens 76-80 17403097-9 2007 VSMC ability to synthesize PGE(2) and PGI(2) fitted mPGES-1 and COX-2 expression, respectively. Prostaglandins I 38-41 prostaglandin E synthase Mus musculus 52-59 17403097-9 2007 VSMC ability to synthesize PGE(2) and PGI(2) fitted mPGES-1 and COX-2 expression, respectively. Prostaglandins I 38-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 17403097-12 2007 CONCLUSIONS: mPGES-1 is the main PGES responsible for PGE(2) biosynthesis by VSMC and its induction downregulates VSMC ability to produce PGI(2.) Prostaglandins I 138-141 prostaglandin E synthase Mus musculus 13-20 17403097-12 2007 CONCLUSIONS: mPGES-1 is the main PGES responsible for PGE(2) biosynthesis by VSMC and its induction downregulates VSMC ability to produce PGI(2.) Prostaglandins I 138-141 prostaglandin E synthase Homo sapiens 14-18 17485013-9 2007 Aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiated the contractile response of gastroepiploic artery to adrenergic stimulation by inhibiting COX-2-derived PGI(2). Prostaglandins I 192-195 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 17374479-5 2007 Pretreatment with PX-18 to inhibit secretory PLA(2) or BEL to inhibit calcium-independent PLA(2) prior to thrombin or tryptase stimulation resulted in a significant inhibition of both PGI(2) and PGE(2) release. Prostaglandins I 184-187 phospholipase A2 group IB Homo sapiens 45-51 20641513-7 2004 Stimulation of the ETB receptors on the endothelium results in the release of nitric oxide and prostacyclins, which culminates in vasodilation (9). Prostaglandins I 95-108 endothelin receptor type B Homo sapiens 19-22 17374479-5 2007 Pretreatment with PX-18 to inhibit secretory PLA(2) or BEL to inhibit calcium-independent PLA(2) prior to thrombin or tryptase stimulation resulted in a significant inhibition of both PGI(2) and PGE(2) release. Prostaglandins I 184-187 phospholipase A2 group IB Homo sapiens 90-96 17374479-5 2007 Pretreatment with PX-18 to inhibit secretory PLA(2) or BEL to inhibit calcium-independent PLA(2) prior to thrombin or tryptase stimulation resulted in a significant inhibition of both PGI(2) and PGE(2) release. Prostaglandins I 184-187 coagulation factor II, thrombin Homo sapiens 106-114 17374734-3 2007 In human lung cancer, prostacyclin synthase (PGIS) and PGI2 are down-regulated, whereas PGE2 synthase (PGES) and PGE2 are up-regulated. Prostaglandins I 45-49 prostaglandin I2 synthase Homo sapiens 22-43 17328923-2 2007 PGI synthase (PGIS) catalyzes the isomeization of PGH(2) to prostacyclin (PGI(2)). Prostaglandins I 0-3 prostaglandin I2 (prostacyclin) synthase Mus musculus 14-18 20641230-6 2004 Stimulation of the ETB receptors on the endothelium itself results in the release of nitric oxide and prostacyclins, which culminates in vasodilation (9). Prostaglandins I 102-115 endothelin receptor type B Homo sapiens 19-22 17374734-4 2007 Murine carcinogenesis models of human lung cancer reciprocate the relationship between PGIS and PGES expression. Prostaglandins I 87-91 prostaglandin E synthase Homo sapiens 96-100 17023553-7 2007 OVX-induced decreases in gastric tissue levels of CGRP and 6-keto-PGF(1alpha), a stable metabolite of PGI(2), in rats were reversed by estradiol and isoflavone. Prostaglandins I 102-105 calcitonin-related polypeptide alpha Rattus norvegicus 50-54 17148578-8 2007 These data suggest that PPARdelta may play an important role in lipid metabolic and signalling pathways during embryo organogenesis, developmental pathways that are altered in embryos from diabetic rats, possibly as a result of a reduction in levels of PPARdelta and its endogenous activator PGI(2). Prostaglandins I 292-295 peroxisome proliferator-activated receptor delta Rattus norvegicus 24-33 17148578-8 2007 These data suggest that PPARdelta may play an important role in lipid metabolic and signalling pathways during embryo organogenesis, developmental pathways that are altered in embryos from diabetic rats, possibly as a result of a reduction in levels of PPARdelta and its endogenous activator PGI(2). Prostaglandins I 292-295 peroxisome proliferator-activated receptor delta Rattus norvegicus 253-262 17087955-1 2006 BACKGROUND & AIMS: Sensory neurons play a critical role in reducing stress-induced gastric mucosal injury by releasing calcitonin gene-related peptide (CGRP) through an increase in gastric mucosal levels of prostacyclin (PGI(2)). Prostaglandins I 225-228 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 156-160 17187424-0 2007 Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Prostaglandins I 0-15 prostaglandin-endoperoxide synthase 2 Mus musculus 62-78 17187424-6 2007 Treatment of COX-2(-/-) mice with misoprostol (a PGE(1/2) analog) or beraprost (a PGI(2) analog) significantly decreased ConA-induced liver injury. Prostaglandins I 82-85 cytochrome c oxidase II, mitochondrial Mus musculus 13-18 16973753-6 2006 mPGES-1 deletion augmented expression of both prostacyclin (PGI(2)) and thromboxane (Tx) synthases in endothelial cells, and VSMCs expressing PGI synthase were enriched in mPGES-1(-/-) LDLR(-/-) lesions. Prostaglandins I 60-63 prostaglandin E synthase Mus musculus 0-7 16973753-7 2006 Stimulation of mPGES-1(-/-) VSMC and macrophages with bacterial LPS increased PGI(2) and thromboxane A(2) to varied extents. Prostaglandins I 78-81 prostaglandin E synthase Mus musculus 15-22 16973753-11 2006 Inhibitors of mPGES-1 may be less likely than those selective for cyclooxygenase 2 to result in cardiovascular complications because of a divergent impact on the biosynthesis of PGI(2). Prostaglandins I 178-181 prostaglandin E synthase Mus musculus 14-21 16954456-9 2006 CONCLUSIONS: COX-2 plays an essential part in cardioprotection of the delayed phase of EPC in rats, which might be related to actions of PGE(2) or PGI(2), or both. Prostaglandins I 147-150 cytochrome c oxidase II, mitochondrial Rattus norvegicus 13-18 16750518-10 2006 In human umbilical-cord veins endothelial cells, BE-I-PLA2 was neither apoptotic nor proliferative but stimulated endothelial cells to release prostaglandin I(2), suggesting an increase of its potential anti-platelet activity in vivo. Prostaglandins I 143-158 phospholipase A2 group IIA Homo sapiens 54-58 20477620-7 2006 COX-1 plays an active role in atherogenesis via thromboxane A(2), while COX-2-derived prostaglandin (PGI(2)) protects against atherosclerosis in murine models. Prostaglandins I 101-104 cytochrome c oxidase II, mitochondrial Mus musculus 72-77 16418176-6 2006 Significant inhibition of chemically induced skin carcinogenesis was observed in both wild-type and PPARbeta-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE(2) and PGI(2). Prostaglandins I 232-235 peroxisome proliferator activator receptor delta Mus musculus 100-108 16651465-9 2006 The hypertension of salt-fed adiponectin KO mice was associated with reduced mRNA levels of endothelial NO synthase (eNOS) and prostaglandin I(2) synthase in aorta and low metabolite levels of endothelial NO synthase and prostaglandin I(2) synthase in plasma. Prostaglandins I 127-142 adiponectin, C1Q and collagen domain containing Mus musculus 29-40 16651465-9 2006 The hypertension of salt-fed adiponectin KO mice was associated with reduced mRNA levels of endothelial NO synthase (eNOS) and prostaglandin I(2) synthase in aorta and low metabolite levels of endothelial NO synthase and prostaglandin I(2) synthase in plasma. Prostaglandins I 221-236 adiponectin, C1Q and collagen domain containing Mus musculus 29-40 16423868-1 2006 In Sertoli epithelial cells, the IL-1beta induces prostaglandins (PG) PGE(2), PGF(2alpha) and PGI(2) (7-, 11-, and 2-fold, respectively), but not PGD(2), production. Prostaglandins I 94-97 interleukin 1 beta Homo sapiens 33-41 16614756-2 2006 These inhibitors are believed to exert both their beneficial and their adverse effects by suppression of PGHS-2-derived prostacyclin (PGI(2)) and PGE(2). Prostaglandins I 134-137 prostaglandin-endoperoxide synthase 2 Mus musculus 105-111 16614756-4 2006 Here, selective inhibition, knockout, or mutation of PGHS-2, or deletion of the receptor for PGHS-2-derived PGI(2), was shown to accelerate thrombogenesis and elevate blood pressure in mice. Prostaglandins I 108-111 prostaglandin-endoperoxide synthase 2 Mus musculus 93-99 16614756-7 2006 We show that deletion of mPGES-1 depressed PGE(2) expression, augmented PGI(2) expression, and had no effect on thromboxane biosynthesis in vivo. Prostaglandins I 72-75 prostaglandin E synthase Mus musculus 25-32 16614756-9 2006 These results suggest that inhibitors of mPGES-1 may retain their antiinflammatory efficacy by depressing PGE(2), while avoiding the adverse cardiovascular consequences associated with PGHS-2-mediated PGI(2) suppression. Prostaglandins I 201-204 prostaglandin E synthase Mus musculus 41-48 16614756-9 2006 These results suggest that inhibitors of mPGES-1 may retain their antiinflammatory efficacy by depressing PGE(2), while avoiding the adverse cardiovascular consequences associated with PGHS-2-mediated PGI(2) suppression. Prostaglandins I 201-204 prostaglandin-endoperoxide synthase 2 Mus musculus 185-191 16373414-8 2006 Stimulation of Ishikawa cells and human endometrial biopsy explants with 100 nm iloprost (a PGI analog) rapidly activated ERK1/2 signaling and induced the expression of proangiogenic genes, basic fibroblast growth factor, angiopoietin-1, and angiopoietin-2, in an epidermal growth factor receptor (EGFR)-dependent manner. Prostaglandins I 92-95 mitogen-activated protein kinase 3 Homo sapiens 122-128 16454737-8 2006 Prostacyclins are powerful vasodilators and potent inhibitors of platelet aggregation which are produced from free arachidonic acid through the catalytic activity of two COX: COX-1 and COX-2. Prostaglandins I 0-13 mitochondrially encoded cytochrome c oxidase I Homo sapiens 175-180 16432508-6 2006 A correlation between COX-2 expression and PGI(2) and PGE(2) release was detected. Prostaglandins I 43-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 16918352-5 2006 Attenuation of inflammatory responses by sensory neuron activation can be explained mainly by CGRP-induced increase in the endothelial production of prostacyclin (PGI(2)). Prostaglandins I 163-166 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 94-98 16236816-11 2006 These results suggest that endogenous PGs derived from COX-2 play a crucial role in gastric mucosal defense during I/R, and this action is mainly mediated by PGI(2) through the activation of IP receptors. Prostaglandins I 158-161 cytochrome c oxidase II, mitochondrial Mus musculus 55-60 16454737-8 2006 Prostacyclins are powerful vasodilators and potent inhibitors of platelet aggregation which are produced from free arachidonic acid through the catalytic activity of two COX: COX-1 and COX-2. Prostaglandins I 0-13 mitochondrially encoded cytochrome c oxidase II Homo sapiens 185-190 16533160-3 2006 This review provides information regarding the most current advances in the findings of the molecular mechanisms for PGI(2) biosynthesis in the endoplasmic reticulum (ER) membrane through the coordination between PGI(2) synthase and its upstream enzymes, cyclooxygenase-1 (COX-1) or -2 (COX-2), and for PGI(2) signaling through its cell membrane receptors and nuclear peroxisome proliferator-activated receptors. Prostaglandins I 117-120 prostaglandin-endoperoxide synthase 1 Homo sapiens 255-271 16533160-3 2006 This review provides information regarding the most current advances in the findings of the molecular mechanisms for PGI(2) biosynthesis in the endoplasmic reticulum (ER) membrane through the coordination between PGI(2) synthase and its upstream enzymes, cyclooxygenase-1 (COX-1) or -2 (COX-2), and for PGI(2) signaling through its cell membrane receptors and nuclear peroxisome proliferator-activated receptors. Prostaglandins I 117-120 mitochondrially encoded cytochrome c oxidase I Homo sapiens 273-285 16054700-3 2006 In response to changes in environmental factors such as oxygen tension, blood flow, circulating cytokines, and growth factors, the endothelium synthesizes and/or extracts many vasoactive mediators such as endothelin-1 (ET-1), norepinephrine, angiotensin 1, thromboxane, prostacyclin (PGI(2)), and the endothelial-derived relaxing factor nitric oxide (NO). Prostaglandins I 284-287 endothelin 1 Homo sapiens 205-217 16533160-3 2006 This review provides information regarding the most current advances in the findings of the molecular mechanisms for PGI(2) biosynthesis in the endoplasmic reticulum (ER) membrane through the coordination between PGI(2) synthase and its upstream enzymes, cyclooxygenase-1 (COX-1) or -2 (COX-2), and for PGI(2) signaling through its cell membrane receptors and nuclear peroxisome proliferator-activated receptors. Prostaglandins I 117-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 287-292 15985651-1 2005 PGE(2) and PGI(2) stimulate renin secretion and cAMP accumulation in juxtaglomerular granular (JG) cells. Prostaglandins I 11-14 renin Homo sapiens 28-33 17332682-3 2006 On the other hand, they modify synthesis and release of PGI(2) and NO via increasing production of other biologically important peptides like bradykinin, Ang-(1-7) or Ang-(1-9). Prostaglandins I 56-59 kininogen 1 Homo sapiens 142-152 17332682-3 2006 On the other hand, they modify synthesis and release of PGI(2) and NO via increasing production of other biologically important peptides like bradykinin, Ang-(1-7) or Ang-(1-9). Prostaglandins I 56-59 angiopoietin 1 Homo sapiens 154-162 17332682-3 2006 On the other hand, they modify synthesis and release of PGI(2) and NO via increasing production of other biologically important peptides like bradykinin, Ang-(1-7) or Ang-(1-9). Prostaglandins I 56-59 angiopoietin 1 Homo sapiens 167-175 16297610-2 2006 In an extension of these studies, we now report that prior intraperitoneal administration of PGE(1), PGE(2), PGF(1)(alpha), and PGF(3)(alpha) prevented alloxan-induced diabetes mellitus in male Wistar rats, whereas PGI(2), TXB(2), and 6-keto PGF(1)(alpha) were not that effective. Prostaglandins I 215-218 placental growth factor Rattus norvegicus 109-112 16297610-2 2006 In an extension of these studies, we now report that prior intraperitoneal administration of PGE(1), PGE(2), PGF(1)(alpha), and PGF(3)(alpha) prevented alloxan-induced diabetes mellitus in male Wistar rats, whereas PGI(2), TXB(2), and 6-keto PGF(1)(alpha) were not that effective. Prostaglandins I 215-218 placental growth factor Rattus norvegicus 128-131 16297610-2 2006 In an extension of these studies, we now report that prior intraperitoneal administration of PGE(1), PGE(2), PGF(1)(alpha), and PGF(3)(alpha) prevented alloxan-induced diabetes mellitus in male Wistar rats, whereas PGI(2), TXB(2), and 6-keto PGF(1)(alpha) were not that effective. Prostaglandins I 215-218 placental growth factor Rattus norvegicus 128-131 16221213-1 2005 BACKGROUND: Prostaglandins such as prostaglandin E(2) (PGE(2)) and prostaglandin I(2) (PGI(2)) counteract the angiotensin II (Ang II)-induced vasoconstriction in the glomerular microcirculation. Prostaglandins I 67-82 angiotensinogen Rattus norvegicus 110-132 16221213-1 2005 BACKGROUND: Prostaglandins such as prostaglandin E(2) (PGE(2)) and prostaglandin I(2) (PGI(2)) counteract the angiotensin II (Ang II)-induced vasoconstriction in the glomerular microcirculation. Prostaglandins I 87-90 angiotensinogen Rattus norvegicus 110-132 15886804-10 2005 Elevating cAMP levels with PGI(2) or forskolin precludes thrombin-induced p27 and p31 tyrosine phosphorylation. Prostaglandins I 27-31 coagulation factor II, thrombin Homo sapiens 57-65 15886804-10 2005 Elevating cAMP levels with PGI(2) or forskolin precludes thrombin-induced p27 and p31 tyrosine phosphorylation. Prostaglandins I 27-31 interferon alpha inducible protein 27 Homo sapiens 74-77 15886804-10 2005 Elevating cAMP levels with PGI(2) or forskolin precludes thrombin-induced p27 and p31 tyrosine phosphorylation. Prostaglandins I 27-31 proteasome 26S subunit, non-ATPase 8 Homo sapiens 82-85 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 fms related receptor tyrosine kinase 1 Bos taurus 56-63 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 kinase insert domain receptor Bos taurus 68-75 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 fms related receptor tyrosine kinase 1 Bos taurus 89-96 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 vascular endothelial growth factor A Bos taurus 56-60 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 vascular endothelial growth factor A Bos taurus 148-154 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 fms related receptor tyrosine kinase 1 Bos taurus 89-96 15637071-9 2005 In summary, our data demonstrate that the activation of VEGFR-1 and VEGFR-2 heterodimer (VEGFR-1/R-2) is essential for PGI(2) synthesis mediated by VEGF-A(165) and VEGF-A(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 homodimers with corresponding agonists. Prostaglandins I 119-122 kinase insert domain receptor Bos taurus 246-253 16115891-6 2005 In the present study, we investigated the effect of PGI(2) on HIF-1 regulation in human umbilical vein endothelial cells under prolonged hypoxia (12 h). Prostaglandins I 52-56 hypoxia inducible factor 1 subunit alpha Homo sapiens 62-67 15713689-4 2005 A small reduction in NGF expression and/or secretion was also observed with adiponectin and prostaglandins PGE(2), PGF(2alpha), and PGI(2). Prostaglandins I 132-135 nerve growth factor Mus musculus 21-24